The physiological activity of stomach and esophagus is often impaired by the onset of various diseases such as Gastroesophageal Reflux Disease (GERD), esophagitis, hiatal hernia, tertiary esophageal waves, Barrett’s esophagus, achalasia, gastritis, peptic ulcers, esophageal and gastric cancer.

These pathologies present different symptomatology that could be classified as gastro-esophageal and extra gastro-esophageal and the current pharmacological treatments are poor in providing comprehensive therapeutic support with good efficacy and safety.

Refluward® HA is an innovative nutraceutical formulation with two patented technologies named WARDIMIX® and MUCEDIG®. A total of 40 patients suffering of four different conditions correlated with gastro-esophageal area such as gastro-esophageal reflux, reflux esophagitis, hiatal hernia and tertial esophageal waves with both typical and atypical GERD symptomatology were enrolled in the present retrospective clinical survey.

Refluward® HA oral administration after one month reduced the total symptomatology of gastro-esophageal diseases according to two different questionnaire used RSI and GIS score. Moreover, continuing the therapy up to 3 months, a further reduction in the symptomatology was obtained without any side effect or drop out. More consistent randomized and placebo-controlled studies considering also plasmatic or endoscopic data are necessary to confirm Refluward® HA as a novel therapeutic potential treatment for different gastro-esophageal diseases.